1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol, 2023, 20(9): 624-639.
|
3. |
World Health Organization (WHO). Global Health Estimates (GHE). 2020.
|
4. |
国家卫生健康委办公厅. 原发性肺癌诊疗指南(2022年版). 协和医学杂志, 2022, 13(4): 549-570.
|
5. |
Rongshou Z, Siwei Z, Shaoming W, et al. Lung cancer incidence and mortality in China: Updated statistics and an overview of temporal trends from 2000 to 2016. J Nat Can Cent, 2022, 2(3): 139-147.
|
6. |
Li C, Lei S, Ding L, et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl), 2023, 136(13): 1583-1590.
|
7. |
Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer, 2012, 131(5): 1210-1219.
|
8. |
邹小农, 贾漫漫, 王鑫, 等. 《2020全球癌症报告》要点解读. 中国胸心血管外科临床杂志, 2021, 28(1): 11-18.
|
9. |
Ervik M, Lam F, Laversanne M, et al. Global Cancer Observatory: Cancer Over Time (International Agency for Research on Cancer). URL: https://gco.iarc.fr/overtime. Accessed on 1 May 2022.
|
10. |
GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: A systematic analysis from the Global Burden of Disease Study 2019. Lancet, 2021, 397(10292): 2337-2360.
|
11. |
Jiang D, Zhang L, Liu W, et al. Trends in cancer mortality in China from 2004 to 2018: A nationwide longitudinal study. Cancer Commun (Lond), 2021, 41(10): 1024-1036.
|
12. |
Parascandola M, Xiao L. Tobacco and the lung cancer epidemic in China. Transl Lung Cancer Res, 2019, 8(Suppl 1): S21-S30.
|
13. |
Hosgood HD 3rd, Boffetta P, Greenland S, et al. In-home coal and wood use and lung cancer risk: A pooled analysis of the International Lung Cancer Consortium. Environ Health Perspect, 2010, 118(12): 1743-1747.
|
14. |
Kurmi OP, Arya PH, Lam KB, et al. Lung cancer risk and solid fuel smoke exposure: A systematic review and meta-analysis. Eur Respir J, 2012, 40(5): 1228-1237.
|
15. |
Qiu AY, Leng S, McCormack M, et al. Lung effects of household air pollution. J Allergy Clin Immunol Pract, 2022, 10(11): 2807-2819.
|
16. |
Singh N, Agrawal S, Jiwnani S, et al. Lung cancer in India. J Thorac Oncol, 2021, 16(8): 1250-1266.
|
17. |
Kaur H, Sehgal IS, Bal A, et al. Evolving epidemiology of lung cancer in India: Reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key. Indian J Cancer, 2017, 54(1): 285-290.
|
18. |
Mohan A, Garg A, Gupta A, et al. Clinical profile of lung cancer in North India: A 10-year analysis of 1862 patients from a tertiary care center. Lung India, 2020, 37(3): 190-197.
|
19. |
Shaikh R, Janssen F, Vogt T. The progression of the tobacco epidemic in India on the national and regional level, 1998-2016. BMC Public Health, 2022, 22(1): 317.
|
20. |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
|
21. |
Jani C, Marshall DC, Singh H, et al. Lung cancer mortality in Europe and the USA between 2000 and 2017: An observational analysis. ERJ Open Res, 2021, 7(4): 00311-2021.
|
22. |
Forsea AM. Cancer registries in Europe-going forward is the only option. Ecancermedicalscience, 2016, 10: 641.
|
23. |
中国省区水平肺癌死亡率估计方法研究. 第二届国家癌症中心学术年会论文集. 2012: 34.
|
24. |
中国疾病预防控制中心. 2018 年中国成人烟草调查结果. 2019. URL:http://www.chinacdc.cn/yw_9324/201905/t20190530_202932.html.
|
25. |
GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: A systematic analysis from the Global Burden of Disease Study 2015. Lancet, 2017, 389(10082): 1885-1906.
|
26. |
Bruce N, Dherani M, Liu R, et al. Does household use of biomass fuel cause lung cancer? A systematic review and evaluation of the evidence for the GBD 2010 study. Thorax, 2015, 70(5): 433-441.
|
27. |
Koo LC, Ho JH. Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol, 1990, 19(Suppl 1): S14-S23.
|
28. |
Perrotta F, D'Agnano V, Scialò F, et al. Evolving concepts in COPD and lung cancer: A narrative review. Minerva Med, 2022, 113(3): 436-448.
|
29. |
Qi C, Sun SW, Xiong XZ. From COPD to lung cancer: Mechanisms linking, diagnosis, treatment, and prognosis. Int J Chron Obstruct Pulmon Dis, 2022, 17: 2603-2621.
|
30. |
El Rayes T, Catena R, Lee S, et al. Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1. Proc Natl Acad Sci USA, 2015, 112(52): 16000-16005.
|
31. |
Sigel K, Makinson A, Thaler J. Lung cancer in persons with HIV. Curr Opin HIV AIDS, 2017, 12(1): 31-38.
|
32. |
Shiels MS, Cole SR, Mehta SH, et al. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr, 2010, 55(4): 510-515.
|
33. |
Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS, 2012, 26(8): 1017-1025.
|
34. |
Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol, 2006, 24(9): 1383-1388.
|
35. |
Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS, 2007, 21(2): 207-213.
|
36. |
Kirk GD, Merlo C, O' Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis, 2007, 45(1): 103-110.
|
37. |
Patel P, Hanson DL, Sullivan PS, et al. Adult and adolescent spectrum of sisease project and HIV outpatient study investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med, 2008, 148(10): 728-736.
|
38. |
Rivera C, Pecuchet N, Wermert D, et al. Obesity and lung cancer: Incidence and repercussions on epidemiology, pathology and treatments. Rev Pneumol Clin, 2015, 71(1): 37-43.
|
39. |
Wang G, Qiu M, Xing X, et al. Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis. Sci Transl Med, 2022, 14(630): eabk2756.
|
40. |
World Health Organization (WHO). WHO global report on trends in prevalence of tobacco use 2000-2025(third edition). URL: WHO global report on trends in prevalence of tobacco use 2000-2025, fourth edition.
|
41. |
《“健康中国2030”规划纲要》. 中国肿瘤, 2019, 28(10): 724.
|
42. |
《健康中国行动(2019-2030)》. 中国组织工程研究, 2020, 24(36): 5905.
|
43. |
陈悦. 我国高发生活方式病研究. 遵义医科大学, 2022.
|
44. |
Adams SJ, Stone E, Baldwin DR, et al. Lung cancer screening. Lancet, 2023, 401(10374): 390-408.
|
45. |
赫捷, 李霓, 陈万青, 等. 中国肺癌筛查与早诊早治指南(2021, 北京). 中国肿瘤, 2021, 30(2): 81-111.
|
46. |
Kee D, Wisnivesky J, Kale MS. Lung cancer screening uptake: Analysis of BRFSS 2018. J Gen Intern Med, 2021, 36(9): 2897-2899.
|
47. |
Cao W, Tan F, Liu K, et al. Uptake of lung cancer screening with low-dose computed tomography in China: A multi-centre population-based study. EClinica lMedicine, 2022, 52: 101594.
|
48. |
Quaife SL, Ruparel M, Dickson JL, et al. Lung Screen Uptake Trial (LSUT): Randomized controlled clinical trial testing targeted invitation materials. Am J Respir Crit Care Med, 2020, 201(8): 965-975.
|
49. |
Fitzgerald RC, Antoniou AC, Fruk L, et al. The future of early cancer detection. Nat Med, 2022, 28(4): 666-677.
|
50. |
Liu MC, Oxnard GR, Klein EA, et al. CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol, 2020, 31(6): 745-759.
|
51. |
Hubbell E, Clarke CA, Aravanis AM, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev, 2021, 30(3): 460-468.
|
52. |
Hackshaw A, Cohen SS, Reichert H, et al. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Br J Cancer, 2021, 125(10): 1432-1442.
|
53. |
潘世泽, 汪巍, 方一凡, 等. 叶酸受体阳性循环肿瘤细胞检测对早期肺癌的诊断效能. 山东医药, 2017, 57(47): 69-72.
|
54. |
Zhou Q, Geng Q, Wang L, et al. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness. EBioMedicine. 2019, 41: 236-243.
|
55. |
Pérol M, Felip E, Dafni U, et al. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol, 2022, 33(5): 511-521.
|
56. |
Pan Y, Liu X, Zhang W, et al. Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion. Lung Cancer, 2023, 181: 107233.
|
57. |
Febbraro M, Gheware A, Kennedy T, et al. Barriers to access: Global variability in implementing treatment advances in lung cancer. Am Soc Clin Oncol Educ Book, 2022, 42: 1-7.
|
58. |
董懂, 黄意恒, 张亚杰, 等. 《中华医学会肺癌临床诊疗指南(2023版)》解读. 中国胸心血管外科临床杂志, 2023, 30(11): 1533-1538.
|